medicaldevice-network.com
Biomerica’s tests for IBD conditions gain CE-marking under EU’s IVDR
A CE mark under the EU IVDR means a new non-invasive test aimed at identifying dietary triggers for people with UC or Crohn’s may become available in Europe. Tests like this could affect how some patients and clinicians think about diet-based symptom management.
Adults with ulcerative colitis or Crohn’s disease interested in diet-related symptom management, gastroenterologists, and clinicians evaluating new diagnostics.
What To Know
Biomerica has received CE-marking under the EU IVDR for food intolerance tests tailored for ulcerative colitis and Crohn’s disease. The article describes these as non‑invasive, personalised tests that detect dietary triggers linked to inflammation and says the CE mark will support European market access and broader international expansion.
The company frames the certification as meeting IVDR safety and performance requirements and part of its product launch plans. The report focuses on regulatory clearance and potential market availability rather than clinical data. It does not provide study results, diagnostic accuracy metrics, or details about which specific biomarkers are measured.
It also does not claim changes to clinical guidelines or recommend treatment changes. If you have UC or Crohn’s and are interested in diet-driven symptom management, this may be a diagnostic product to watch for availability in Europe, but discuss any test results with your gastroenterologist before changing treatment or diet.
This is a regulatory/market update: the article reports CE marking and planned product launch but provides no clinical performance data or peer-reviewed evidence. CE marking indicates conformity with EU device rules but is not the same as clinical guideline endorsement.
Patients should wait for published accuracy data and professional guidance before using results to change care.
